• Neethu Wilson
• Ashik S S
• Ajina Kamal
• E . Sam Jeeva Kumar
• Dr . Prasobh G R

ABSTRACT Novel oral anticoagulants commonly known as NOACs are the non vitamin k antagonist oral anticoagulants which are newer the market .It has displaced vitamin k antagonist oral anticoagulants mainly Warfarin for many indications .Novel oral anticoagulants are a main class of drug of choice to prevent stroke in patients with non valvular atrial fibrillation and to prevent and treat venous thromboembolism. Two classes of NOACs are currently available : Direct thrombin inhibitors such as Dabigatran and the Direct inhibitors of Xa factor such as Rivaroxaban ,Apixaban and Edoxaban. Compared to vitamin K antagonist oral anticoagulants, these drugs have a fixed dosing with no need for INR monitoring ,a wider therapeutic range, rapid onset and short half lives and few drug and food interactions.

Novel oral anticoagulants ,Vitamin K antagonist ,Direct thrombin inhibitor ,Direct Xa factor inhibitor ,Dabigatran, Rivaroxaban, Edoxaban, Apixaban, Venous thromboembolism ,Non valvular atrial fibrillation.

"Overview of The New Oral Anticoagulants : Novel Oral Anticoagulants .", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 5, page no.b529-b535, May-2022, Available :http://www.jetir.org/papers/JETIR2205173.pdf

"Overview of The New Oral Anticoagulants : Novel Oral Anticoagulants .", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 5, page no. ppb529-b535, May-2022, Available at : http://www.jetir.org/papers/JETIR2205173.pdf